Skip to main content
editorial
. 2023 May 22;12(3):435–439. doi: 10.21037/hbsn-23-203

Table 2. IMbrave050 safety summary.

Events Atezo + bev (n=332) Active surveillance (n=330)
Treatment duration, median, months Atezo: 11.1, Bev: 11.0 NA
Treatment AE (%) 88.3 NA
Grade 3/4 AE (%) 41.0 13.3
Serious AE (%) 24.1 10.3
Grade 5 AE (%) 1.8 0.3
AE leading to dose interruption of any study treatment (%) 46.7 NA
AE leading to withdrawal from any study treatment (%) 19.0 NA

AE, adverse event, NA, not applicable.